Randomised Controlled Trials in Diabetes Research : A Pathway to Interpreting Published Results
Battelino, Tadej (Univerza V Ljubljani)
Mauricio, Didac (Institut d'Investigació Biomèdica Sant Pau)

Date:	2021
Abstract:	Key Summary Points: Randomised controlled trials (RCTs) remain the gold standard for direct treatment comparisons. However, interpreting the results of RCTs and making judgements about the quality of evidence and how results may be applicable to diabetes management can be difficult for healthcare practitioners (HCPs). In this article, a checklist of the points that we consider most important when reading and interpreting RCT publications is summarised, and may serve as useful guidance for HCPs.
Note:	Altres ajuts: Ferrer, GluSense, Zealand, Eli Lilly and Company, Novartis, Sanofi, Medtronic, MSD, Sandoz, Abbott Diabetes Care, AstraZeneca España, Boehringer Ingelheim España, GSK, Roche España, Novo Nordisk
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	CONSORT ; Interpretation ; Publications ; Randomised controlled trial
Published in:	Diabetes Therapy, Vol. 12 Núm. 10 (october 2021) , p. 2635-2644, ISSN 1869-6961

DOI: 10.1007/s13300-021-01143-6
PMID: 34455574

10 p, 341.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles